Journal Article

Issues in antiplatelet therapy for UA/NSTEMI

K. Chatterjee, J. Col, A.J. Dalby and D. Gulba

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 3, issue suppl_J, pages J24-J31
Published in print August 2001 | ISSN: 1520-765X
Published online August 2001 | e-ISSN: 1554-2815 | DOI: http://dx.doi.org/10.1016/S1520-765X(01)90137-3
Issues in antiplatelet therapy for UA/NSTEMI

Show Summary Details

Preview

Options for antiplatelet therapy have increased in the last decade, with thienopyridines and GP IIb/IIIa receptor antagonists joining aspirin on the roster of available antiplatelet agents. Both North American (ACC/AHA) and European (ESC) cardiology societies have made recommendations regarding the use of antiplatelet agents in recently issued practice guidelines for the management of acute coronary syndromes without ST-segment elevation. In September 2000, a group of international cardiologists meeting under the auspices of the International Cardiology Forum participated in a workshop to examine the new antiplatelet recommendations. Workshop participants generally agreed that both sets of guidelines were satisfactory, however there were areas of disagreement. The most controversial topic was the role of GP IIb/IIIa antagonists. Given the evidence for efficacy of these agents for medical management, many participants felt that their use was overemphasized. There was strong support for the use of GP IIb/IIIa inhibitors in the setting of intervention, although cost is prohibitive in many countries. In view of real-world limitations, guidelines for alternative management strategies are needed.

Keywords: Antiplatelet; GP IIb/IIIa antagonist; acute coronary syndromes; unstable angina; guidelines

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.